Deciparticle™ Platform
Ultra-small <20nm particles engineered for deeper tumor penetration
Pipeline
SAPU-003 and next-gen Deciparticles in development
News
Latest: SAPU-003 Phase 1/2 update
Deciparticle™ Technology
Sapu Nano’s Deciparticle™ platform creates sub-20nm particles with enhanced tumor penetration, improved biodistribution, and programmable drug-nanoparticle behavior. These precision ultrasmall structures are engineered to overcome delivery barriers and maximize therapeutic impact.
Our Clinical Pipeline
SAPU-003 — Everolimus Deciparticle™ (IV), Phase 1/2
Designed to improve tumor penetration and deliver full systemic exposure through sub-20nm delivery.
Deciparticle™ Platform — Next-Generation Programs
Additional sub-20nm nanomedicine candidates are advancing through preclinical and early-stage development.